Improved Breast MRI With SWIFT
| Status: | Completed |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 4/2/2016 |
| Start Date: | August 2009 |
| End Date: | March 2015 |
| Contact: | Diane Hutter, RN |
| Email: | hutte019@umn.edu |
| Phone: | 612-625-2350 |
Improved Breast Dynamic Contrast Enhanced-magnetic Resonance Imaging (DCE-MRI) With Sweep Imaging With Fourier Transform (SWIFT)
Today's medical imaging methods have insufficient specificity for reliable differentiation
between benign and malignant breast lesions in patients. Pathologic evaluation is currently
the only way to obtain a definitive diagnosis. This research will use a novel method of
magnetic resonance imaging (MRI), Sweep Imaging with Fourier Transform (SWIFT), at a very
high magnetic field (4 Tesla) to distinguish malignant from benign breast lesions. This
research will reveal whether the SWIFT sequence bears new capabilities in medical imaging
for breast cancer diagnosis.
between benign and malignant breast lesions in patients. Pathologic evaluation is currently
the only way to obtain a definitive diagnosis. This research will use a novel method of
magnetic resonance imaging (MRI), Sweep Imaging with Fourier Transform (SWIFT), at a very
high magnetic field (4 Tesla) to distinguish malignant from benign breast lesions. This
research will reveal whether the SWIFT sequence bears new capabilities in medical imaging
for breast cancer diagnosis.
Patients will be asked to come to the Center for Magnetic Resonance Research (CMRR) at the
University of Minnesota. Researchers will interview the patient and describe procedures and
risks. An intravenous (IV) line will be placed in an upper extremity for infusing magnetic
resonance imaging (MRI) contrast dye. Baseline MRI scans will be done. These MRI
measurements will be compared with clinical, radiological and pathological findings (the
gold standard).
Follow-up contact will occur within one year after the MRI to determine whether a pathology
report is available.
University of Minnesota. Researchers will interview the patient and describe procedures and
risks. An intravenous (IV) line will be placed in an upper extremity for infusing magnetic
resonance imaging (MRI) contrast dye. Baseline MRI scans will be done. These MRI
measurements will be compared with clinical, radiological and pathological findings (the
gold standard).
Follow-up contact will occur within one year after the MRI to determine whether a pathology
report is available.
Inclusion Criteria:
- Women with a clinically or mammographically identified suspicious breast mass that is
likely to be biopsied or surgically removed.
Exclusion Criteria:
- Pregnancy
- Ferromagnetic implants
- History of shotgun wounds and shrapnel
- Obesity (>250 pounds)
- Cardiac pacemaker
- Incompatible implanted medical device
- Severe claustrophobia
- Major surgeries with potential of ferromagnetic implants
- Severe asthma and allergies
- i-STAT system, a handheld blood analyzer (I-STAT) creatinine test, estimated
glomerular filtration rate (GFR) <30
- Metallic object (greater than 2 cm in length) in the breast
- Metallic ink tatoo within 20 cm of the breast (approximately 8 inches)
We found this trial at
1
site
Click here to add this to my saved trials
